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ABSTRACT
Purpose: To evaluate chemoprevention by celecoxib in cases of reflux-induced gastric adenocarcinoma, in Wistar rats that underwent
gastrojejunostomy. Methods: Sixty male Wistar rats of average age three months underwent surgery and were distributed into three
groups: group 1, exploratory laparotomy; group 2, gastrojejunostomy; and group 3, gastrojejunostomy and daily celecoxib administration.
After 53 weeks, the animals were sacrificed. Changes in the mucosa of the gastric body of group 1 and in the gastrojejunal anastomosis
of groups 2 and 3, observed in histopathological and immunohistochemical examinations, were compared. All statistical analyses were
performed using Epi-Info®, version 3.4.3. Results: Comparison between groups 2 and 3 relative to the presence of adenocarcinoma
showed a statistically significant difference (p=0.0023). Analysis of the association between groups 2 and 3 relative to COX-2 expression
also showed a statistically significant difference (p=0.0018). Conclusion: Celecoxib had an inhibiting effect on gastric carcinogenesis
induced by enterogastric reflux in an animal model.
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RESUMO
Objetivo: Avaliar a quimioprevenção pelo celecoxibe no adenocarcinoma gástrico induzido por refluxo, em ratos Wistar, submetidos a
gastrojejunostomia. Métodos: Sessenta ratos machos Wistar, com média de idade de três meses foram operados e distribuídos em 03
grupos: Grupo 1 - Os animais foram submetidos a laparotomia exploradora. Grupo 2 - Os animais foram submetidos a gastrojejunostomia.
Grupo 3 - Os animais foram submetidos a gastrojejunostomia e tomaram celecoxib, diariamente. Após um período de 53 semanas, os
animais foram sacrificados. As alterações da mucosa do corpo gástrico dos animais do grupo 1 e da  anastomose gastrojejunal dos
animais dos grupos 2 e 3 foram analisadas no exame histopatológico e imuno-histoquímica e foram comparadas. Todas as análises
estatísticas foram realizadas pelo programa Epi Info®, versão 3.4.3. Resultados: No cotejo entre os animais dos grupos 2 e 3 com
relação à presença de adenocarcinoma observou-se uma diferença estatística significante (p=0,0023). A análise de associação entre os
grupos 2 e 3 com relação à expressão da COX-2, também evidenciou uma diferença estatística significante (p=0,0018). Conclusão: O
celecoxib teve efeito inibidor da carcinogênese gástrica, induzida pelo refluxo em ratos.
Descritores: Adenocarcinoma. Estômago. Quimioprevenção. Inibidores de ciclooxigenase. Ratos.
1Research performed at the Postgraduate Gastroenterological Surgery Programs, Federal University of Sao Paulo (UNIFESP) and University of Health
Sciences of Alagoas (UNCISAL).
Introduction
Cyclooxygenase, also known as prostaglandin en-
doperoxide synthase, is the key enzyme needed for prostaglandin
synthesis from arachidonic acid. Two types of cyclooxygenase have
been identified: COX-1 and COX-2. In many situations, COX-1
enzyme is produced constitutively in the gastric mucosa, while
there is high production of COX-2 at inflammation sites and in
neoplastic tissue1,2,3.
Over the last few years, celecoxib (a specific COX-2
inhibitor) has been used to reduce the number of polyps in a rat
model for adenomatous polyposis and in cases of duodenal
adenomatous polyposis in humans4,5. This drug is believed to act
primarily by inhibiting the cyclooxygenase enzyme, with the
advantages of having fewer gastric and renal side effects and not
inhibiting platelet function.
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Chemoprevention is taken to mean the use of drugs or
natural agents with the purpose of preventing, inhibiting or to re-
versing the processes of carcinogenesis6.
Some unanswered questions motivated us to evaluate
chemoprevention by celecoxib in cases of reflux-induced gastric
adenocarcinoma, in Wistar rats that were subjected to the carcino-
genic model of gastrojejunostomy7,8,9,10,11,12.
Methods
This study was approved by the Research Ethics Com-
mittees of the Postgraduate Surgery Programs of UNIFESP and
UNCISAL.
Sixty male Wistar rats, of average age three months and
average weight 300g and acclimatized to the conditions of the vi-
varium of the Foundation and University of Health Sciences of
Alagoas (UNCISAL), underwent surgery with intra-abdominal
anesthesia of ketamine hydrochloride (50 mg/ml), at a dosage of
0.2 ml/100g of the animal’s weight. The animals were randomly
divided into three groups: group 1, consisting of 10 animals that
underwent explorative laparotomy; group 2, consisting of 25 ani-
mals that underwent gastrojejunostomy; and group 3, consisting of
25 animals that underwent gastrojejunostomy and received
celecoxib orally (10 mg/kg/day). After a 53-week observation pe-
riod, the animals were sacrificed and their stomachs were removed
for macro and microscopic analysis.
Anatomopathological examination
1 – First stage (hematoxylin-eosin staining). All the sur-
gical specimens were fixed in buffered formalin and the routine
used in the pathology laboratory of Santa Casa de Misericórdia of
Maceió, Alagoas, was followed. The mucosa of the gastric body of
the group 1 animals and mucosa of the gastrojejunal anastomoses
of the group 2 and 3 animals were evaluated and compared. The
microscopic mucosal abnormalities found were chronic gastritis,
foveolar hyperplasia, intestinal metaplasia, dysplasia and adeno-
carcinoma. Chronic gastritis was defined by the presence of mono-
nuclear cells in the submucosa and lamina propria of the stomach.
Foveolar hyperplasia was defined as stretching and twisting of the
gastric foveolae. Intestinal metaplasia was recognized morphologi-
cally by the presence of goblet cells13. The definition and classifi-
cation of dysplasia obeyed the criteria proposed by Ming et al.14.
Adenocarcinoma was defined by the presence of atypical gastric
glandules that invaded the submucosa, muscularis propria or se-
rosa15.
For the purposes of analyzing the occurrences of chronic
gastritis, the foveolar hyperplasia and intestinal metaplasia were
grouped and named inflammatory-metaplastic abnormalities.
2 – Second stage (immunohistochemistry). Representa-
tive blocks were selected from each case for immunohistochemi-
cal examination by means of the two-stage polymer technique, us-
ing the polyclonal antibody anti-COX-2/H62 (Santa Cruz Biotech-
nology Inc, USA), in accordance with Shi et al.16. The negative
control was processed without the primary antibody and the posi-
tive control was obtained from cases of gastric adenocarcinoma
that were already known to express COX-2.
Immunohistochemical evaluation
A Leitz optical microscope was used, with magnifications
of 40x and 400x. The analysis was performed by two pathologists
without previous knowledge of the study groups. COX-2 expres-
sion was deemed to be present when fine granulation of brown
color was observed in the cytoplasm of the tumor cells17.
Statistical methods
All the statistical analyses (frequencies of adenocarcinoma,
dysplasia, inflammatory-metaplastic lesions and analyses of asso-
ciations between groups 2 and 3) were performed using the Epi-
Info® software, version 3.4.3. For the nullity hypothesis, p was set
to be less than 5% or 0.05. An asterisk (*) was placed on the cases
with statistical significance.
Results
Inflammatory-metaplastic lesions were observed in 12
cases (48%) among the group 2 animals and in 24 cases (96%)
among the group 3 animals. Chronic gastritis, foveolar hyperplasia
and intestinal metaplasia were included. No microscopic ab-
normalities of the gastric mucosa were observed in the group 1
animals.
A slight degree of dysplasia was observed in three cases
(12%) among the group 2 animals. There was no dysplasia among
the group 1 and 3 animals.
Adenocarcinoma was observed in 10 cases (40%) among
the group 2 animals and in one case (4%) in group 3. All the
tumors presented vegetative growth, of well-differentiated type,
and had developed at the level of the gastrojejunal anastomosis
(Figures 1 and 2).
Adenocarcinoma Duodenum 
Efferent loop Afferent loop 
FIGURE 1 – Photograph of a stomach with adenocarcinoma and
anatomical references
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Fisher’s exact test, p= 0.0023*; Odds Ratio: 16 (1.85 – 137.97); RR: 10 (1.38 – 72.39)
FIGURE 2 – Photomicrograph of a well-differentiated adenocarcinoma.
Hematoxylin-eosin (40x)
In this experiment, COX-2 expression was observed in
four out of the 36 cases (11.1%) of inflammatory-metaplastic
lesions, in one out of the three cases (33.3%) of dysplasia and in
nine out of the eleven cases (81.8%) of adenocarcinoma (Figures 3
and 4).
FIGURE 3 – Photomicrograph of a well differentiated adenocarcinoma.
Fine brown-stained cytoplasmic pigmentation. Positive for COX-2
(two-stage polymer technique, 40x)
FIGURE 4 – Photomicrograph of a well-differentiated adenocarcinoma.
Fine brown-stained cytoplasmic pigmentation. Positive for COX-2
(two-staged polymer technique, 400x)
Comparison between groups 2 and 3 in relation to the
presence of adenocarcinoma showed a statistically significant
difference in adenocarcinoma development: Fisher’s exact test,
p=0.0023*; Odds Ratio: 16 (1.85-137.97); RR: 10 (1.38-72.39)
(Table 1).
TABLE 1 – Analysis of the association between groups 2 and 3 in relation to the presence of gastric
adenocarcinoma
Cancer   
Yes No TOTAL 
              
GROUP 
Frequency % Frequency %   
Group 2 10 40 15 60 25 
Group 3 1 4 24 96 25 
TOTAL 11 22 39 78 50 
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Discussion
In studies on gastric carcinogenesis, rats have often been
used to evaluate lesions induced by carcinogens8,9, enterogastric
reflux10,11, Helicobacter pylori infection12 or associations between
these agents8,9,12. An enterogastric reflux model was used in this
experiment, without gastric resection, since this is less traumatic
and easy to reproduce. After a 53-week period, the animals were
sacrificed and their stomachs were analyzed. The macroscopic and
microscopic abnormalities observed were most evident at the level
of the gastrojejunal anastomosis, and the histological analyses were
therefore focused on that region.
Adenocarcinoma was observed in 10 cases (40%) among
the group 2 animals and in one case (4%) among the group 3
animals. There were no cases among the group 1 animals. All the
tumors presented vegetative growth, of well-differentiated type,
and they developed at the level of the gastrojejunal mucosa, close
to the afferent jejunal loop. No cases of metastatic dissemination
to the liver or abdominal cavity were observed. The incidence of
adenocarcinoma in models for reflux-induced gastric carcinogen-
esis has ranged from 7 to 70.8% (mean of 31%) among the various
authors8,9,10,11,18. The reasons for this diversity of results may be
due to differences in the intensity of the reflux provided by the
techniques used, in exposure duration and in the susceptibility of
the rat lineages used. By choosing gastrojejunostomy as the model
for enterogastric reflux in cases of gastric carcinogenesis, the
multiple stages of this chain of events from chronic gastritis to
intestinal metaplasia, dysplasia and, finally, adenocarcinoma were
demonstrated.
COX-2 expression was not detected in the normal gastric
mucosa in this study, using optical microscopy. However, using
electron microscopy, another study has already reported detection
of immunoreactivity of mucosal cell cytoplasm in the fundus and
pylorus regions of rats19. Other researchers, investigating COX-2
expression in gastrointestinal tract tissues of rats, dogs, monkeys
and humans, by means of immunoblot and biochemical techniques,
have found variations in its expression between these segments,
along with differences between the species. COX-2 expression was
Analysis of the association between groups 2 and 3 in
relation to COX-2 expression showed a statistically significant
TABLE 2 – Analysis of the association between groups 2 and 3 in relation to COX-2 expression
Fisher’s exact test, p=0.0018*; Odds Ratio: 10.10 (2.05 - 54.95); RR: 6.00 (1.49 – 24.10)
COX-2   
Yes No TOTAL GROUP 
Frequency % Frequency %   
Group 2 12 48 13 52 25 
Group 3 2 8 23 92 25 
TOTAL 14 28 36 72 50 
Analysis of the association between COX-2 expression
and gastric adenocarcinoma in groups 2 and 3 showed a statisti-
cally significant difference between the adenocarcinoma that
TABLE 3 – Analysis of the association between COX-2 expression and gastric adenocarcinoma in groups 2 and 3
Fisher’s exact test, p=0.000034*; Odds Ratio: 27.29 (4.99 – 230.94); RR: 11.57 (2.84 – 47.03)
Cancer   
Yes No TOTAL COX-2 
Frequency % Frequency %   
Yes 9 64.3 5 35.7 14 
No 2 5.6 34 94.4 36 
TOTAL 11 22 39 78 50 
difference: Fisher’s exact test, p=0.0018*; Odds Ratio: 10.10
(2.05 – 54.95); RR: 6.00 (1.49 – 24.10) (Table 2).
expressed COX-2 and the adenocarcinoma that did not express it:
Fisher’s exact test, p=0.000034*; Odds Ratio: 27.29 (4.99 – 230.94);
RR: 11.57 (2.84 – 47.03) (Table 3).
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shown in only three macrophages out of 22 rats examined20. In the
present study, it was observed in one out of the three cases of dys-
plasia (33.3%) among the group 2 animals. With regard to adeno-
carcinoma, expression was observed in nine out of eleven cases
(81.8%), in the tumor cell cytoplasm. These results, relating to
COX-2 expression in gastric adenocarcinoma in rats, have never
been published previously in the literature. In clinical studies,
COX-2 was expressed in 51 to 76% (mean of 73%) of gastric
tumors according to Northern blot or RT-PCR, in 67 to 83% (mean
of 73%) according to Western blot and in 43 to 100% (mean of
62%) according to immunohistochemistry21. The great variability
in the expression of this protein in literature can be explained by
the use of many types of antibodies, the differences in the methods
used for quantifying reaction positivity and the way in which the
specimens were fixed. Because this is an immunological reaction,
antigen recovery depends on the state of conservation of the paraffin
blocks and the adequacy of specimen fixing in buffered formalin.
Use of inadequate solutions of formalin may block the protein bind-
ing sites on the antibody, thereby not allowing antigen recovery.
Comparing groups 2 and 3 in relation to the presence of
adenocarcinoma, a statistically significant difference between the
animals in these groups was observed with regard to cancer devel-
opment, such that the group 3 animals were protected from having
cancer through the use of celecoxib (p=0.0023). It was also ob-
served, in analyzing the association between groups 2 and 3 in
relation to COX-2 expression, that the group 2 animals had statis-
tically significant greater COX-2 expression than seen in the group
3 animals (p=0.0018). Analysis of the association between COX-2
expression and adenocarcinoma in groups 2 and 3, a statistically
significant difference was observed between the adenocarcinomas
that expressed COX-2 and those that did not express it
(p=0.000034). Some other studies have proved that the specific
COX-2 inhibitor (celecoxib) and sulindac have a chemopreventive
effect in animal models that have been inoculated with human gas-
tric cancer cells (xenografts)22,23. In another study, celecoxib and
indomethacin were also effective in inhibiting the growth of lin-
eages of human gastric cancer cells (AGS and MKN), through in-
ducing apoptosis and stopping the cell cycle and not by suppress-
ing COX-2 and prostaglandin E2
24. In a model for gastric carcino-
genesis using N-methyl-N’-nitro-N-nitrosoguanidine (MNNG),
celecoxib and indomethacin were observed to provide
chemoprevention by a mechanism independent of COX-225. A
complementary study comparing the kinetic cell abnormalities in
the gastric mucosa of rats treated with celecoxib at the dosages of
5, 10 and 20 mg/kg/day and indomethacin found that treatment
with both drugs inhibited the proliferation of the gastric tumor in
over 65% of the cases (p<0.02). Celecoxib induced increased
apoptosis at a dependent dosage (p<0.05), and was most evident at
the dosage of 10 mg/kg/day26.
In our experiment, celecoxib was observed to be effective
for chemoprevention against carcinogenesis induced by
enterogastric reflux. The mechanisms responsible for this
chemopreventive action are not well known. However, it is known
that the main mechanism for the action of this drug as an anti-
inflammatory and analgesic agent would be through inhibition of
cyclooxygenase-2, thereby blocking the synthesis of prostaglan-
dins from arachidonic acid. There is evidence that chemopreventive
mechanisms may function through inhibition of angiogenesis ei-
ther via a COX-dependent route or not. Other mechanisms could
arise through induction of tumor cell apoptosis or inhibition of cell
proliferation. We believe that the chemoprevention mechanism of
this drug may result from the sum of the effects already mentioned.
Conclusion
Celecoxib had an inhibiting effect on reflux-induced
gastric carcinogenesis in rats.
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